Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » Medicine » Cancer » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Theory of Literature
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
01.Experimental Leukemia: History, Biology and Genetics
02.Cancer Metastasis Research: Pathological Insight
03.Eye Cancer Research Progress
04.Mesothelioma from Bench Side to Clinic
05.Photodynamic Therapy: New Research
06.Cancer and Stem Cells
07.Oncology Social Work Practice in the Care of Breast and Ovarian Cancer Survivors
08.Progress in Oral Cancer Research
09.New Research on Cutaneous Lymphomas
10.Aromatase Inhibitors: Types, Mode of Action and Indications
Notifications more
NotificationsNotify me of updates to Ovarian Cancer: New Research (Horizons in Cancer Research, Volume 19)
Tell A Friend
Tell someone you know about this product.
Ovarian Cancer: New Research (Horizons in Cancer Research, Volume 19)
Retail Price: $110.00
10% Online Discount
You Pay:

Editors: Bardos, A. P.
Book Description:
This new volume presents the latest research on therapies for ovarian cancer. Ovarian cancer is cancer that begins in the cells that constitute the ovaries, including surface epithelial cells, germ cells, and the sex cord-stromal cells. Cancer cells that metastasize from other organ sites to the ovary (most commonly breast or colon cancers) are not then considered ovarian cancer. According to the American Cancer Society, ovarian cancer accounts for 4 percent of all cancers among women and ranks fifth as a cause of their deaths from cancer. The American Cancer Society statistics for ovarian cancer estimate that there will be 25,400 new cases and 14,300 deaths in 2003. The death rate for this disease has not changed much in the last 50 years. Unfortunately, almost 70 percent of women with the common epithelial ovarian cancer are not diagnosed until the disease is at an advanced stage—i.e., has spread to the upper abdomen (stage III) or beyond (stage IV). The 5-year survival rate for these women is only 15 to 20 percent, whereas the 5-year survival rate for stage I disease patients approaches 90 percent and for stage II disease patients approaches 70 percent.

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.

Table of Contents:

Progress in Ovarian Cancer Research
(Dilek Aktas, Hacettepe University School of Medicine, Turkey)

Ovulation and Ovarian Surface Epithelial Cancer
(William J. Murdoch and Anna C. McDonnel, University of Wyoming)

Ovarian Sertoli-Leydig Cell Tumors with Heterologous Elements
(Evanthia Kostopoulou, University of Thessaly, Greece and Alexander Talerman, Thomas Jefferson University)

Interleukin-1 System and Sex Steroid Receptor Gene Expression in Human Endometrial Cancer
(G. Hudelist et al., Ludwig Boltzmann Institute of Clinical Experimental Oncology, Vienna, Austria)

Role of Membrane-Associated Serine/Threonine Phosphatase in Ovarian Cancer Cell Survival: Evidence for Minor Role of Apoptosis in Gonadotropin-Releasing Hormone’s Antiproliferative Signaling
(Michiyo Sugiyama et al., Gifu University School of Medicine, Japan)

Docetaxel in Combination with Carboplatin as First-Line Chemotherapy for Patients with Epithelial Ovarian Cancer
(Yoichi Aoki and Kenichi Tanaka, Niigata University Graduate School of Medical and Dental Sciences, Japan)

Immunospecific Albumin Microspheres as Delivery System for Cisplatin and 5-Fluorouracil for the Treatment of Ovarian Adenocarcinoma
(Ernest J. Truter and Aldina S. Santos, Cape Technikon, South Africa)

Strategies for Improving Outcome in Ovarian Cancer – the Role of Surgery
(Karsten Münstedt et al., Justus-Liebig-University of Giessen, Germany)

Should Systematic Lymphadenectomy be Performed in Suboptimally Debulked Patients with Stage III Ovairan Carcinoma? A DEGOG Study
(Ugar Syagili et al., Dokuz Eylul University School of Medicine, Turkey)

Outcomes for Surgery in Ovarian Cancer
(L. Elit, McMaster University, Canada)

Do Ascites, Mass Volume and Peritoneal Caarcinomatosis Effect Serum CA-125 Levels in Patients with Ovarian Carcinoma? A Different Point of View
(Ugar Saygili, Dokuz Eylul Universityu School of Medicine, Turkey)

The Usefulness of Serum CA-125 Levels in the Prediction of Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma
Ugur Saygili, Serkan Guclu and Oktay Erten; Universityu School of Medicine, Turkey

Perceived Risk of Ovarian Cancer, Worry about Ovarian Cancer Risk, and Use of Ovarian Cancer Screening by Women at Risk for Ovarian Cancer
(M. Robyn Andersen et al., Fred Hutchinson Cancer Research Center)

New Strategy for the Treatment of Ovarian Cancer with the Aim of Conquest of Chemoresistance
(Junzo Kigawa et al., Tottori University School of Medicine, Japan)

Treatment Decision Making in Ovarian Cancer
(L. Elit, McMaster University, Canada)


      Horizons in Cancer Research
   Binding: Hardcover
   Pub. Date: 2009 3rd quarter
   ISBN: 978-1-59454-241-1
   Status: AV
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2022

Ovarian Cancer: New Research (Horizons in Cancer Research, Volume 19)